138 related articles for article (PubMed ID: 15753455)
1. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Wong ET
Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455
[No Abstract] [Full Text] [Related]
2. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Wong ET; Tishler R; Barron L; Wu JK
Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
[TBL] [Abstract][Full Text] [Related]
3. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Pitini V; Arrigo C; Righi M
Cancer; 2004 Dec; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
[No Abstract] [Full Text] [Related]
4. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
[TBL] [Abstract][Full Text] [Related]
5. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
[TBL] [Abstract][Full Text] [Related]
6. Rituximab maintenance therapy in central nervous system lymphoma?
Murawski N; Pfreundschuh M
Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
[No Abstract] [Full Text] [Related]
7. Temozolomide as salvage treatment in primary brain lymphomas.
Reni M; Zaja F; Mason W; Perry J; Mazza E; Spina M; Bordonaro R; Ilariucci F; Faedi M; Corazzelli G; Manno P; Franceschi E; Pace A; Candela M; Abbadessa A; Stelitano C; Latte G; Ferreri AJ
Br J Cancer; 2007 Mar; 96(6):864-7. PubMed ID: 17325700
[TBL] [Abstract][Full Text] [Related]
8. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O
Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
Nayak L; Abrey LE; Drappatz J; Gilbert MR; Reardon DA; Wen PY; Prados M; Deangelis LM; Omuro A;
Leuk Lymphoma; 2013 Jan; 54(1):58-61. PubMed ID: 22656234
[TBL] [Abstract][Full Text] [Related]
10. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Yamanaka R
Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
[TBL] [Abstract][Full Text] [Related]
11. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Glass J; Won M; Schultz CJ; Brat D; Bartlett NL; Suh JH; Werner-Wasik M; Fisher BJ; Liepman MK; Augspurger M; Bokstein F; Bovi JA; Solhjem MC; Mehta MP
J Clin Oncol; 2016 May; 34(14):1620-5. PubMed ID: 27022122
[TBL] [Abstract][Full Text] [Related]
12. [Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Wakabayashi T
Gan To Kagaku Ryoho; 2009 Jun; 36(6):938-40. PubMed ID: 19579330
[No Abstract] [Full Text] [Related]
13. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
[TBL] [Abstract][Full Text] [Related]
14. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
Coiffier B; Radford J; Bosly A; Martinelli G; Verhoef G; Barca G; Davies A; Decaudin D; Gallop-Evans E; Padmanabhan-Iyer S; Van Eygen K; Wu KL; Gupta IV; Lin TS; Goldstein N; Jewell RC; Winter P; Lisby S;
Br J Haematol; 2013 Nov; 163(3):334-42. PubMed ID: 24032456
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
Baruchel S; Diezi M; Hargrave D; Stempak D; Gammon J; Moghrabi A; Coppes MJ; Fernandez CV; Bouffet E
Eur J Cancer; 2006 Sep; 42(14):2335-42. PubMed ID: 16899365
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
[TBL] [Abstract][Full Text] [Related]
17. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
[TBL] [Abstract][Full Text] [Related]
18. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Khasraw M; Bell D; Wheeler H
J Clin Neurosci; 2009 Jun; 16(6):854-5. PubMed ID: 19303779
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A
Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172
[TBL] [Abstract][Full Text] [Related]
20. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
Pels H; Schulz H; Schlegel U; Engert A
Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]